DNAzymes have the potential to suppress gene expression through sequence-specific mRNA cleavage and can therefore play an important role in various gene therapies. Hepatitis B virus (HBV) is still one of the most serious liver infections in people around the world and is difficult to treat. We previously designed a 10-23 DNAzyme called DrzBS, which targets HBV S gene expression, but this enzyme depends on exogenous delivery, and so its application has been limited. To overcome this limitation, we have now developed a chitosan-based nanocarrier (chitosan-g-stearic acid, CSO-SA) for intracellular delivery of 
Introduction
Hepatitis B, resulting from the infection of the hepatitis B virus (HBV), is one of the world's most common and serious infectious diseases. About two billion people globally have been exposed to the infection 1 and more than 250 million people are suffering from chronic HBV infection. [2] [3] [4] Twenty-ve percent of all chronic HBV carriers develop serious liver diseases, such as chronic hepatitis, cirrhosis and primary hepatocellular carcinoma.
5,6
HBV-related liver diseases still cause an estimated 500 000 to one million deaths per year worldwide.
7-9 Viral mutations 10 and patient immune tolerances to HBV antigens are the main causes of persistent chronic HBV infection. Therefore, reactivation of HBV-specic immune responses is essential to reduce morbidity and mortality from chronic HBV infection.
HBV is an enveloped virus and can only infect humans and primates. The S gene codes for the viral envelope proteins known as the hepatitis B surface antigen (HBsAg). Recent studies have shown that HBsAg accumulation was associated with specic viral mutations related to disease activities. 11 In addition, when sufficient HBV envelope molecules are present, HBsAg is synthetized much more in excess than required for viral enveloping purposes, and most likely overwhelms any benet of anti-HBs responses, causing immune tolerance. Persistence of HBsAg production is associated with an increased risk of liver cancer, even in the absence of productive HBV replication. 12 Inhibition of HBsAg expression is a critical step in the functional control of HBV infection. It will unveil the unmaking of the existing anti-HBs response, which would favor clearance of virions, both infectious and noninfectious. 13, 14 In other words, the ability to clear HBsAg is the next frontier in hepatitis B therapeutics. The achievement of a 'functional cure' for chronic HBV infection with sustained HBsAg clearance, represents the next step in the pace towards HBV elimination. 15 The discovery of DNAzymes breaks the traditional concept of protease-based biocatalysts. A DNAzyme is a structured DNA sequence with catalytic RNA-cleaving activity. The 10-23 DNAzyme consists of a catalytic domain formed by 15 deoxynucleotides in the center with recognition arms formed by seven to ten nucleotides on both sides. 16 The enzyme speci-cally combines with the target mRNA in a highly sequencespecic manner through its recognition arms, while the central catalytic domain cleaves the mRNA target at purinepyrimidine junctions (A-U sites), thereby blocking the expression of the corresponding mRNA and inhibiting the target virus gene expression.
17-21
HBV is an attractive target for the 10-23 DNAzyme, and so we designed the HBV-specic 10-23 DNAzyme named DrzBS. Our previous research showed that DrzBS inhibited the expression of HBV S genes by suppressing the corresponding antigen proteins, thus suggesting that DrzBS could be a powerful, specic, and effective form of anti-HBV gene therapy. In addition, DrzBS has a exible design, independent of cellular mechanisms and does not require expensive chemical modi-cations when be used in vivo. And it does not affect the RNA of the host cell. Thus, DrzBS has a potential application value in anti-HBV gene therapy research. However, a major challenge for the application of the 10-23 DNAzyme is that it cannot replicate endogenously and, consequently, relies on exogenous delivery. Delivery of the 10-23 DNAzyme is limited by poor cellular uptake, rapid degradation by nucleases, and poor endosomal release. Therefore, development of a safe and efficient gene carrier is a prerequisite for successful gene therapy.
22,23
Several non-viral vectors have been developed for DNA delivery that use a wide range of materials such as cationic liposomes, 24, 25 and natural or synthetic polymers. [26] [27] [28] Among these, chitosan has been extensively studied because it is inherently biocompatible, biodegradable, and has low cytotoxicity in comparison to other cationic polymers. 23, [29] [30] [31] Moreover, the positive surface charge and presence of easily modiable primary amines and hydroxyl groups on the chitosan backbone make it an attractive tool for DNAzyme delivery. However, without laborious chemical modications to its structure, it is of limited use as a gene delivery vehicle due to its low ability to efficiently transfect under physiological conditions. 32, 33 To address this problem, our recent studies [34] [35] [36] have demonstrated that chitosan-g-stearic acid (CSO-SA), which is synthesized via a reaction between the carboxyl group of stearic acid and the amine group of chitosan oligosaccharide in the presence of 1-(3-Dimethylamino-propyl)-3-ethylcarbodiimide (EDC), can greatly improve the cellular uptake and in vitro gene transfection efficacy of chitosan. 37, 38 This means that CSO-SA micelles could be an efficient approach for intracellular delivery of the 10-23 DNAzyme.
In this research, we designed and synthesized a kind of 10- 
Results and discussion

Synthesis and characterization of CSO-SA micelles
In this study, the schematic diagram of CSO-SA/DrzBS targeting of cell uptake and intracellular release were shown in Fig. 1 .
The synthesis route of the CSO-SA was shown in Fig. 2a , which was obtained by a coupling reaction between the amino groups of CSO and the carboxyl groups of SA in the presence of EDC. The nal product, CSO-SA, was a white soluble powder aer lyophilization. The chemical structure of CSO-SA was conrmed by 1 H NMR (Fig. 2b) . The peaks at about 1.2 ppm and 0.8 ppm were attributed to the -CH 2 and -CH 3 groups respectively. These results proved the successful synthesis of the CSO-SA micelles. The synthesized CSO-SA could be self-assembly in aqueous solution.
The average size and zeta potential of CSO-SA were 67.3 AE 3.4 nm and 48.3 AE 2.9 mV respectively (Table 1) . However, the values of PI were slightly large, which might due to the micelles dispersed in the deionized water where the pH and ionic strength were unstable. The spherical-like shape of the micelles were revealed with TEM images (Fig. 3) . The CMC of CSO-SA was 75 mg mL
À1
.
Characterization of CSO-SA/DrzBS micelles
Based on the 10-23 DNAzyme molecular structure reported by Santoro and Joyce, 16 we designed and synthesized our 10-23 DNAzyme for the HBV S gene, named DrzBS (Fig. 2c ). DrzBS is a DNA structure that can be combined with CSO-SA by electrostatic interaction to form CSO-SA/DrzBS micelles. The particle size and zeta potential of CSO-SA/DrzBS micelles are presented in Table 1 . The average size was 158.0 AE 2.5 nm and the zeta potential was 39.1 AE 3.3 mV in deionized water. The value of the zeta potential in the CSO-SA and the CSO-SA/DrzBS did not change much, which shows that the composition of the complex is hardly affected by the surface charge of the particles. The TEM photos ( Fig. 3) indicate that CSO-SA/DrzBS micelles had a well-formed shape and compact structure.
Tightlock experiment and DNase I protection assay
Protection of DrzBS from nucleases as well as its polymer binding capability are both crucial factors for its efficient delivery to inhibit HBV gene expression. As the complexes pass through the cytoplasm, this protection effect is important.
39,40
This is because the enzymes and nucleic acids within the cytoplasm make the DrzBS complexes susceptible to hydrolytic and enzymatic degradation. CSO-SA exert the proper protection relied on appropriate N/P ratio. In our previous studies, 41 we have conrmed that CSO-SA micelles became to compact with 10-23 DNAzyme when N/P > 1.2, and further presented a good loading potency at the optimal N/P ratio of 10. In addition, the migration of DrzBS within the CSO-SA/DrzBS complexes was entirely retarded in the loading slot when the N/P ratio was 10. The DNase I protection assay also shown the same results. The naked DrzBS was signicantly degraded, whereas DrzBS combined with the CSO-SA micelles were protected from the attack of DNase I at the N/P ratio of 10 as shown in Fig. 4 .
Cellular uptake
The SD% of CSO-SA, when concentrated in the nucleus and cytoplasm, were measured as 25.31% and 37.92% respectively.
Since the inhibitory effect of DrzBS needs to be exerted in the cytoplasm, we chose the CSO-SA with an SD% of 37.92 AE 0.62%.
In vitro cellular uptake of FITC-labeled micelles on HepG2.2.15 cells were visualized by uorescence microscope at 2 h and 4 h. Fig. 5a shows that the cellular uptake of FITClabeled CSO-SA micelles in cell lines was time dependent. The polymer showed favorable cellular internalization, which mainly depended on the hydrophobic core composed of SA and moderate surface charge. The CLSM results were also shown that the CSO-SA with an SD% of 37.92 AE 0.62% has the ability to target cytoplasm, and the cellular uptake of the CSO-SA micelles is time dependent (Fig. 5b) . These results suggested that CSO-SA micelles were efficient intracellular delivery systems and could improve the cellular uptake into HepG2.2.15 cells.
In vitro cytotoxicity
A good quality vector should be biocompatible and not damage the cell structure or its normal function. To examine the cytotoxicity of the CSO-SA and Lipofectamine™ 2000, cell viability was determined by MTT assay. Fig. 6a shows that CSO-SA micelles exhibit excellent cell compatibility in HepG2.2.15 and L02 (non-tumour hepatocytes) cells, whereas the cytotoxicity of Lipofectamine™ 2000 was found to be much higher, as previously reported. 42 The half maximal inhibitory concentration (IC 50 (Fig. 6b) .
The cytotoxicity of Lipofectamine™ 2000 may be a result of its high positive surface charges and its aggregation on cell surfaces, thus impairing important membrane functions. 28, 43, 44 In contrast, the sources for CSO-SA synthesis, CSO and SA, were either biodegradable, low toxic or biocompatible. Compared with Lipofectamine™ 2000, CSO-SA micelles had relatively low cytotoxicity. Together, these internalization and cytotoxicity results veried that the CSO-SA is safe and has potential as an anti-HBV gene therapy.
Transfection and inhibitory effects of DrzBS on HBsAg expression in HepG2.2.15 cells
Our experiments showed that the inhibition percentages of HBsAg expression in the HepG2.2.15 cells by our CSO-SA complexes were 16.7 AE 3.2% (for the N/P ratio ¼ 5 : 1) and 51.3 AE 4.6% (for the N/P ratio ¼ 10 : 1) (p < 0.001, Fig. 7a ). This conrms that the N/P ratio of 10 : 1 achieves the best To further understand the potential mechanism of the decreased cytotoxicity and intracellular effects observed with CSO-SA/DrzBS micelles, we examined their inhibitory effect on S gene expression over time and at the same concentration (1.2 mmol L À1 ). Fig. 7c showed the HBsAg inhibition effect aer transfection. It was obvious that DrzBS cannot inhibit HBsAg itself, and the CSO-SA has a slight inhibition of HBsAg but H NMR spectra, from top to bottom: chitosan, stearic acid, and CSO-SA. The signals assigned to the -CH 2 -(1.2 ppm) and -CH 3 -(0.8 ppm) SA were detectable on the CSO-SA spectra. nucleotide.
Synthesis of chitosan-g-stearic acid (CSO-SA)
Chitosan oligosaccharide was prepared according to the previous study. 45 CSO-SA was then synthesized via a reaction of the carboxyl group of stearic acid with the amine group of the chitosan oligosaccharide in the presence of EDC. 46 Briey, SA , SD% is the degrees of amino-substitution. and EDC were dissolved in acetone and then added into an ethanol-acetone mixed solvent (ethanol : acetone ratio ¼ 3 : 7, v/v). The mixture was stirred for 0.5 h at 60 C. CSO (MW 18.4 kDa) was then dissolved in hot water, aer which the SA/EDC mixture was added dropwise. The reaction solution was stirred for another 6 h and was then dialyzed against deionized water using a dialysis membrane (molecular weight cut-off (MWCO): 7 kDa, Spectrum Laboratories, Laguna Hills, CA) for 48 h. Finally, the product was collected by lyophilization followed by a further wash with ethanol to remove products. The washed product was then collected by lyophilization again.
Preparation of Lipofectamine™ 2000/DrzBS and CSO-SA/ DrzBS micelles
The Lipofectamine™ 2000/DrzBS complex was prepared by gently mixing DrzBS with Lipofectamine™ 2000 in 50 mL OPTI-MEMI (total volume: 100 mL), followed by incubation for 20 min at room temperature. CSO-SA solutions with different concentrations (dissolved in 25 mM sodium acetate buffer, pH 5.5) were rst puried with a 0.22 m Millipore lter. CSO-SA/DrzBS micelles with various N/ P ratios (The N/P ratio is the number of unreacted free primary amines of CSO-SA to the number of phosphate groups of DrzBS) were prepared by mixing appropriate volumes of CSO-SA micelle solutions with DrzBS solutions (diluted with water, 500 mg mL À1 ). Aer mixing in a vortex for 30 s, the mixtures were incubated for 30 min at 37 C. Electrophoresis was then carried out with a current of 100 V for 20 min in a TAE buffer solution (40 mM Tris-HCl, 1% (v/v) acetic acid, 1 mM EDTA).
Characterization of CSO-SA and CSO-SA/DrzBS micelles
The chemical structure of CSO-SA was determined with 1 H nuclear magnetic resonance (NMR) spectroscopy, and this chemical was dispersed in D 2 O at pH 7 and 25 C. The substitution degree (SD%) of amino groups of CSO-SA, dened as the molar ratio of stearate to anhydroglucosidic units in chitosan oligosaccharide, was detected with TNBS, and the ultraviolet (UV) absorbance of the nal reaction mixture at 344 nm was measured by UV spectroscopy (TU-1800PC, Beijing Purkinje General Instrument Co., Ltd., China). The critical micelle concentration (CMC) of CSO-SA was measured by pyrene uo-rescence using a uorometer (F-2500, Hitachi Co., Japan). The intensity ratio (I 1 : I 3 ) of the rst peak (I 1 , 374 nm) to the third peak (I 3 , 385 nm) in the pyrene emission spectra was analyzed to calculate the CMC. The size and zeta potential of CSO-SA micelles and CSO-SA/ DrzBS micelles were measured by dynamic light scattering (Zetasizer 3000HS, Malvern Instruments Ltd., UK) in deionized water. Their morphology was examined by transmission electronic microscopy (TEM, Stereoscan, Leica, England).
DNase I protection assay
The DNase I protection assay was performed to investigate the efficiency of the CSO-SA micelles protecting the DrzBS from enzymatic degradation by DNase I. The CSO-SA/DrzBS micelles with 1.2 and 10 of N/P ratios were incubated in a buffer solution (10 mM Tris-HCl, 150 mM NaCl, 1 mM MgCl 2 , pH 7.4) with DNase I (25 units), then shaken at 100 rpm for 30 min at 37 C.
Electrophoresis was conducted in 1% agarose gel with a voltage of 100 V. UV absorbance was measured by UV spectrophotometer at 260 nm (UV-2450, Shimadzu, Japan). cells per well in a 24-well plate and grown for 48 h to allow the cells to attach. Aer the medium was replaced with 0.5 mL OPTI-MEMI, different amounts of CSO-SA/DrzBS micelles (N/P ratio ¼ 10) and Lipofectamine™ 2000/DrzBS (the positive control) were added to each well and incubated with the cells for 6 h. The medium was then replaced with 1 mL of fresh complete medium, and the incubation was continued for a further 12 to 96 h at 37 C. All the experiments were performed in triplicate.
The culture media from the wells were collected for virological assessment. HBsAg production was determined by commercial enzyme immunoassay kits (AXSYM System, Abbott, Wiesbaden, Germany).
Conclusions
In this study, the CSO-SA was synthesized and evaluated as a novel non-viral DNA carrier by binding with a kind of 10-23 DNAzyme named DrzBS, which specically targeted the expression of HBV S genes. The CSO-SA micelles demonstrated superior ability to form nanoscale complexes with DrzBS and had suitable physicochemical properties for DNAzyme delivery, thus nally leading to enhanced gene transfer efficiency, protected DrzBS from degradation, and effectively released DrzBS aer cellular uptake into HepG2.2.15 cells. The CSO-SA/DrzBS micelles signicantly inhibited HBsAg expression in HepG2.2.15 cells compared to Lipofectamine™ 2000/DrzBS micelles (p < 0.001). Most importantly, the inhibitory effect of the CSO-SA/DrzBS micelles on HBV S gene expression could be prolonged to 96 h, which is crucial for anti-HBV gene therapy. In summary, DrzBS delivered by the CSO-SA showed obvious inhibitory effects of HBsAg expression and therapeutic effects, indicating that the CSO-SA was a potential vector for gene therapy and might be used for the successful treatment of chronic HBV carriers.
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